A tertiary care facility experience on pegylated IFN efficacy in chronic hepatitisB patients
Abstract number: P1148
Kurtoglu Gül Y., Bulut C., Kinikli S., Koçak Tufan Z., Ataman Hatipoglu C., Erdinc F.S., Demiroz A.P.
Introduction: Pegylated interferons (Peg-IFN) have been used for the treatment of chronic hepatitis B (CHB). The main properties of these drugs with certain therapy durations and no resistance improvement made them even more preferable. In this study we aimed to evaluate the efficacy of Peg-IFNs in our CHB patients.
Methods: This prospective study was conducted in our clinic between 2006 and 2008. The CHB patients admitted and treated with Peg-IFN are included.
Results: Totally 40 patients (17 female, 23 male) were included. Mean age was 37 (min 16, max 65). 13 of total were HBeAg(+), 24 were Anti-HBeAg(+) while two were both HBeAg(+) and AntiHbe(+) and one was negative for both.
HBeAg (+) patients: They treated for 24 weeks. Virological response rate was 10%, biochemical response rate was 40%, sustained response rate was 10% and primary nonresponse rate was 60% at the end of treatment. Mean alanine aminotransferase (ALT) levels at the beginning and end of treatment were 93.2±52.4 and 73.8±59.7 respectively (p = 0.413). Mean decrease in the HBV DNA level during this perios was 2.4 log10 (p < 0.05). HBeAg seroconversion was seen in two (20%) patients. HBsAg seroconversion was not seen in any patients.
HBeAg(-) patients: They were treated for 48 weeks. Virological and biochemical response rates at the end of treatment were 76% and 67% respectively. Mean ALT levels at the beginning and end of treatment were 116.7±92.4 and 41.5±27.3 respectively (p = 0.003). Mean decrease in the HBV DNA level during this period was 4.3 log10 (p = 0.000). Sustained response rate was 14%. HBsAg seroconversion was seen only in one patient.
Conclusion: Peg-IFN therapy was found to be more effective in HBeAg(-) patients than HBeAg(+) ones. The treatment duration of HbeAg(+) patiens are still not clear and prolonging the treatment time to one year like the negative ones could be detected as well in further studies.
|Session name:||Abstracts 20th European Congress of Clinical Microbiology and Infectious Diseases|
|Location:||Vienna, Austria, 10 - 13 April 2010|
|Back to top|